REG - Alliance Pharma PLC - Update on Timing of Preliminary Results

Alliance PharmaAnnouncement

05/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240405:nRSE4736Ja&default-theme=true

RNS Number : 4736J  Alliance Pharma PLC  05 April 2024

 

 For immediate release  5 April 2024

 

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

 

Update on timing of preliminary results announcement

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that the preliminary results for 2023 are now expected to be published on 23
April 2024. The Group's auditor has determined that the volume of work
required to complete the audit has exceeded its original expectations,
necessitating a short delay in the reporting timetable.

 

Alliance confirms that the details provided in the full year trading update on
29 January 2024 remain accurate.

 

A meeting for analysts will be held at 9.30am on the day of the results at
Buchanan, 107 Cheapside, London. Details of the live webcast of the meeting
will be provided shortly in the investor section of the Alliance website,
https://www.alliancepharmaceuticals.com/investors
(https://www.alliancepharmaceuticals.com/investors) , where a replay will also
be made available following the meeting.

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Deutsche Numis (Nominated Adviser and Joint Broker)                       + 44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Sher Shah

 Investec Bank plc (Joint Broker)                                          + 44 (0)20 7597 5970
 Patrick Robb / Maria Gomez de Olea

 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

 

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

 

Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.

 

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREASLSEDNLEEA